Get Started

MRVI

NASD Maravai Lifesciences Holdings, Inc. Class A
Oct 26, 2026 · 11:14 PM ET EOD Market Closed

$7.58 ↑ +0.00 (+0.00%) Trading Up from the previous close of $7.58, $0.02 below the day’s high of $7.60

YTD change
+133.23%
vs 20-day SMA
+3.17%
vs 200-day SMA
+47.74%

Price ranges

Previous day
$6.98 $7.33
open $7.06 close $7.32
+$0.26 (+3.68%)
Today
$7.32 $7.60
open $7.32 now $7.58
+$0.26 (+3.55%)
Past week
$6.69 $7.62
from $6.79 now $7.58
+$0.79 (+11.63%)
Past month
$6.33 $8.74
from $7.60 now $7.58
-$0.02 (-0.26%)
This year
$2.80 $9.42
from $3.25 now $7.58
+$4.33 (+133.23%)

Price & Performance

+3.90 (+105.98%) / 6M

$3.04$5.17$7.31$9.44Apr 27Jul 28Oct 26

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 88.1% away from all-time highs of $63.55
  • MRVI is up 133% since the beginning of the year
  • MRVI is up 122% over the past 12 months
  • MRVI is down 0% over the past 1 month
  • 12% of all MRVI investors are betting against MRVI

MRVI reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +126.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.02
Earnings momentum +64.5% Quarterly EPS growth
Quarterly change +64.5%

Valuation

P/E ratio N/A
Enterprise value $1.3B
Beta 2.15

Balance sheet & scale

IncomeN/A
Revenue$208.8M
Cash$70.6M
Debt$176.7K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $1.1B

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Competitor comparison

TickerCompany PriceChange
CMXHF CSL Limited $136.90 +0.70%
ARGX argenx SE Sponsored ADR $869.33 -0.50%
ONC BeOne Medicines Ltd. Sponsored ADR $370.87 -1.79%
WXXWY WuXi Biologics (Cayman) Inc. Unsponsored ADR $11.70 +1.30%
INCY Incyte Corporation $113.31 -2.07%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.